Prodrugs pp 1259-1267 | Cite as

Case Study: Fosphenytoin: A Prodrug of Phenytoin

  • Valentino J. Stella
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


Fosphenytoin was designed to be a water-soluble, parenterally safe form of phenytoin, or 5,5-diphenylhydantoin, a sparingly water-soluble (20–30 µg/mL), weakly acidic drug (pKa 8.3) useful in the treatment of epilepsy. To achieve an aqueous solution suitable for parenteral administration, phenytoin was originally formulated as its sodium salt (sodium phenytoin) in a vehicle consisting of 40%propylene glycol and 10% ethanol with a final pH of 12. This formulation can be very toxic, causing severe irritation and pain at the local site of injection and occasional fatalities if injected too rapidly. Sodium phenytoin cannot be administered by intramuscular (IM) injection. Its water-soluble prodrug, fosphenytoin, is formulated in a purely aqueous solution at a pH of about 8.5; it has shown superior safety compared to sodium phenytoin while also permitting IM dosing. Two patents covering fosphenytoin (Stella and Sloan, 1979, 1981) have expired, but two formulation patents are still valid (Herbranson et al., 1990; Stella 2000). An extensive review of the history of fosphenytoin has been published; it includes other examples of prodrugs of phenytoin (Stella, 1996).


Formulation Patent Severe Irritation Phosphate Prodrug High Total Body Clearance Phosphate Ester Prodrug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aweeka FT, Gottwald MD, Gambertoglio JG, Wright TL, Boyer TD, Pollack AS, Eldon MA, Kugler AR, and Alldredge BK, Pharmacokinetics of Fosphenytoin in Patients with Hepatic or Renal Disease. Epilepsia 1999; 40:777–782.PubMedCrossRefGoogle Scholar
  2. Boucher BA, Bombassaro AM, Watridge CB, Achari R, and Turlapaty P. Phenytoin Prodrug Safety, Tolerability and Pharmacokinetics in Patients Following IV and IM Administration. Pharmacother 1988; 8:133–134Google Scholar
  3. Boucher BA, Bombassaro AM, Rasmussen SN, Watridge CB, Achari R, and Turlapaty P. Phenytoin Prodrug 3-Phosphoryloxymethyl Phenytoin (ACC-9653): Pharmacokinetics in Patients Following Intravenous and Intramuscular Administration. J Pharm Sci 1989; 78:929–932PubMedCrossRefGoogle Scholar
  4. Browne TR, Davoudi H, Donn KH, Dougherty CL, Dukes GE, Evans B, Evans JE, Jamerson B, Kres J, McEntegart CM, Messenheimer JA Jr, Powell JR, Quon CY, and Szabo GK. Bioavailability of ACC-9653 (Phenytoin Prodrug). Epilepsia 1989; 30:S27–S32PubMedCrossRefGoogle Scholar
  5. Fechner J, Ihmsen H, Hatterscheid D, Schiessi C, Vornov JJ, Burak E, Scheilden H, and Schuttler J. Pharmacokinetics and Clinical Pharmacokinetics of the New Propofol Prodrug GPI 15715 in Volunteers. Anesthesiol 2003; 99:303–313CrossRefGoogle Scholar
  6. Gerber N, Mays DC, Donn KH, Laddu A, Guthrie RM, Turlapaty P, Quon CY, and Rivenburg WK. Safety, Tolerance and Pharmacokinetics of Intravenous Doses of the Phosphate Ester of 3-Hydroxymethyl-5,5-diphenylhydantoin: A New Prodrug of Phenytoin. J Clin Pharmacol 1988; 28:1023–1032PubMedGoogle Scholar
  7. Heimbach T, Oh DM, Li LY, Forsberg M, Savolainen J, Leppanen J, Matsunaga Y, Flynn G, and Fleischer D. Absorption Rate Limit Considerations for Oral Phosphate Prodrugs. Pharm Res 2003; 20:848–856PubMedCrossRefGoogle Scholar
  8. Herbranson DE, Speicher ER, and Rosenberg LS. Stable Pharmaceutical Composition of 3-(Hydroxymethyl)-5,5-diphenylhydantoin Disodium Phosphate Ester. U.S. patent 4,925,860, May 15, 1990Google Scholar
  9. Jamerson BD, Donn KH, Dukes GE, Messenheimer JA, Brouwer KLR, and Powell JR. Absolute Bioavailability of Phenytoin After 3-Phosphoryloxymethyl Phenytoin Disodium (ACC-9653) Administration to Humans. Epilepsia 1990; 31:592–597PubMedCrossRefGoogle Scholar
  10. Jamerson BD, Dukes GE, Brouwer KLR, Donn KH, Messenheimer JA, and Powell JR. Venous Irritation Related to Intravenous Administration of Phenytoin Versus Fosphenytoin. Pharmacotherapy 1994; 14:47–52PubMedGoogle Scholar
  11. Leppik IE, Boucher BA, Wilder BJ, Murthy VS, Watridge C, Graves NM, Rangel RJ, Rask CA, and Turlapaty P. (1990) Pharmacokinetics and Safety of Phenytoin Prodrug Given IV or IM in Patients. Neurology 1990; 40:456–460PubMedGoogle Scholar
  12. Narisawa S, and Stella VJ. Increased Shelf-Life of Fosphenytoin: Solubilization of a Degradant, Phenytoin, through Complexation with (SBE)7M-β-CD. J Pharm Sci 1998; 87:926–930PubMedCrossRefGoogle Scholar
  13. Pryor FM, Gidal B, Ramsay RE, DeToledo J, and Morgan RO. Fosphenytoin: Pharmacokinetics and Tolerance of Intramuscular Loading Doses. Epilepsia 2001; 42:245–250PubMedCrossRefGoogle Scholar
  14. Ramsay RE, Wilder BJ, Uthman BM, Garnett WR, Pellock JM, Barkley GL, Leppik IE and Knapp LE. Intramuscular Fosphenytoin (Cerebyx) in Patients Requiring a Loading Dose of Phenytoin. Epilepsy Res 1997; 28:181–187PubMedCrossRefGoogle Scholar
  15. Rivenburg W, Gerber N, Donn K, Mays D, Blanski L, Turlapaty P, Laddu A, and Quon CY. Pharmacokinetics and Dose Proportionality of ACC-9653, a Prodrug of Phenytoin in Healthy Volunteers. Fed Proc 1987; 46:708 (Abstract 2289)Google Scholar
  16. Stella VJ, and Sloan KB. Derivatives of 5,5-Diphenylhydantoin Exhibiting Enhanced Solubility and Therapeutic Use Thereof. U.S. Patent #4,163,058 (July 31) 1979Google Scholar
  17. Stella VJ, and Sloan KB. 5,5-Diphenylhydantoins. U.S. Patent #4,260,769 (April 7) 1981Google Scholar
  18. Stella VJ. A Case for Prodrugs, Fosphenytoin. Ad. Drug Del Rev 1996; 19:311–330CrossRefGoogle Scholar
  19. Stella VJ. Polar Drug or Prodrug Compositions with Extended Shelf-life Storage and a Method of Making Thereof. US Patent #6,133,248 (October 17) 2000Google Scholar
  20. TenHoor CN, and Stewart BH. Reconversion of Fosphenytoin in the Presence of Intestinal Alkaline Phosphatase. Pharm Res 1995; 12:1806–1809PubMedCrossRefGoogle Scholar
  21. Varia SA, Schuller S, Sloan KB, and Stella VJ. Phenytoin Prodrugs III: Water-Soluble Prodrugs for Oral and/or Parenteral Use. J Pharm Sci 1984a; 73:1068–1073PubMedCrossRefGoogle Scholar
  22. Varia SA, Schuller S, and Stella VJ. Phenytoin Prodrugs IV: Hydrolysis of Various 3-(Hydroxymethyl)phenytoin Esters. J Pharm Sci 1984b; 73:1074–1080PubMedCrossRefGoogle Scholar
  23. Varia SA, and Stella VJ. Phenytoin Prodrugs V: In Vivo Evaluation of Some Water Soluble Phenytoin Prodrugs in Dogs. J Pharm Sci 1984c; 73:1080–1087PubMedCrossRefGoogle Scholar
  24. Varia SA, and Stella VJ. Phenytoin Prodrugs VI; In Vivo Evaluation of a Phosphate Ester Prodrug of Phenytoin after Parenteral Administration to Rats. J Pharm Sci 1984d; 73:1087–1090PubMedCrossRefGoogle Scholar
  25. Walton NY, and Treiman DM. Comparison of ACC-9653 and Standard Phenytoin in Treatment of Experimental Status Epilepticus. Epilepsia 1989; 30:714–715Google Scholar
  26. Wilder BJ, Ramsay E, Marriott J, Loewen G, and Smith H. (1993) Safety and Tolerance of Intramuscular Administration of Fosphenytoin, a Phenytoin Prodrug, for 5 Days in Patients with Epilepsy. Neurology 1993; 43:A308 (Abstract 582P)Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Valentino J. Stella
    • 1
  1. 1.Department of Pharmaceutical ChemistryThe University of KansasLawrenceUSA

Personalised recommendations